secwatch.observer — SEC 8-K summary
======================================

Issuer:     Milestone Pharmaceuticals Inc. (MIST)
CIK:        0001408443
Form:       8-K
Filed at:   2026-01-26T23:59:59+00:00
Accession:  0001104659-26-006483
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Milestone launches CARDAMYST nasal spray for PSVT via U.S. retail pharmacies
----------------------------------------------------------------------------

- CARDAMYST (etripamil) is now available through U.S. retail pharmacies as first self-administered PSVT treatment.
- National sales force deployment set for mid-February 2026 to support commercialization.
- Eligible commercially insured patients receive a $25 copay cap via patient assistance program.
- FDA approved CARDAMYST on December 12, 2025 — first PSVT therapy approved in over 30 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1408443/000110465926006483/0001104659-26-006483-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1408443/000110465926006483/tm263973d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-006483

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer